Lv71
4560 积分 2021-12-06 加入
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL
15天前
已关闭
Facts and hopes: CAR-T cell therapy and Immune contexture in Non-Hodgkin Lymphoma
15天前
已关闭
Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
15天前
已完结
DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response
15天前
已关闭
Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line
15天前
已关闭
Real-World Treatment Patterns and Out-of-Pocket Costs After CAR T-Cell Therapy in Commercially Insured Patients with B-Cell Non-Hodgkin Lymphoma in the United States
15天前
已关闭
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
19天前
已完结
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
27天前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
30天前
已完结
Long‐Term Issues, Bipolar Disorders and the Self
1个月前
已关闭
Interview with Carlos Caldas
皖公网安备34019202002308
